12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Stalevo levodopa/carbidopa/entacapone regulatory update

Orion disclosed in its 2Q13 earnings that Novartis submitted a regulatory application in Japan for Stalevo levodopa/carbidopa/entacapone to treat Parkinson's disease with end-of-dose motor fluctuations not stabilized on levodopa/carbidopa or levodopa/benserazide...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >